AVIVA STRATEGIES (FKA MGB CONSULTING)

Registrant on federal lobbying filings · filed 2025 to 2026

$1,061,000 Income reported

8 Clients represented

44 Filings counted

0 Former members lobbying

Income is the fees this registrant reported being paid to lobby. 1 filing on this record was restated by a later amendment and is left out of every total here. Everything on this page is grouped by the registrant's LDA id (401109532), not by name.

Clients 8

ENDEAVOR BIOMEDICINES $314,500 8 filings
ELEMENT BIOSCIENCES $283,000 8 filings
ULTRAGENYX PHARMACEUTICAL $114,000 5 filings
ACT FOR ULTRA RARE $112,500 4 filings
BEAM THERAPEUTICS $102,000 6 filings
HUNTINGTON'S DISEASE SOCIETY OF AMERICA $52,500 4 filings
TAYSHA GENE THERAPIES $50,000 5 filings
ARPA-H GO $32,500 4 filings

Reported by year 2 years

2026 $495,000 22 filings
2025 $566,000 22 filings

Issues lobbied 3

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 4

HOUSE OF REPRESENTATIVES 24
SENATE 21
Food & Drug Administration (FDA) 7
Intl Trade Administration (ITA) 4

Recent filings 45 total

Q3 report

ARPA-H GO

3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $12,500 income · posted Oct 19, 2026

View → Q3 report

ACT FOR ULTRA RARE

3rd Quarter 2026 (July 1 - Sep 30) · House · $37,500 income · posted Oct 19, 2026

View → Q3 terminationNo activity

TAYSHA GENE THERAPIES

3rd Quarter 2026 (July 1 - Sep 30) · $20,000 income · posted Oct 19, 2026

View → Q3 report

ENDEAVOR BIOMEDICINES

3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $51,000 income · posted Oct 19, 2026

View → Q3 report

ELEMENT BIOSCIENCES

3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $44,000 income · posted Oct 19, 2026

View → Q2 report

ARPA-H GO

2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $12,500 income · posted Jul 17, 2026

View → Q2 report

ACT FOR ULTRA RARE

2nd Quarter 2026 (Apr 1 - June 30) · House · $37,500 income · posted Jul 17, 2026

View → Q2 terminationNo activity

HUNTINGTON'S DISEASE SOCIETY OF AMERICA

2nd Quarter 2026 (Apr 1 - June 30) · $7,500 income · posted Jul 17, 2026

View → Q2 reportNo activity

TAYSHA GENE THERAPIES

2nd Quarter 2026 (Apr 1 - June 30) · $20,000 income · posted Jul 17, 2026

View → Q2 terminationNo activity

BEAM THERAPEUTICS

2nd Quarter 2026 (Apr 1 - June 30) · posted Jul 17, 2026

View → Q2 report

ENDEAVOR BIOMEDICINES

2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $51,000 income · posted Jul 17, 2026

View → Q2 report

ELEMENT BIOSCIENCES

2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $44,000 income · posted Jul 17, 2026

View → Q1 report

ARPA-H GO

1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $7,500 income · posted Apr 20, 2026

View → Registration

ARPA-H GO

1st Quarter 2026 (Jan 1 - Mar 31) · posted Apr 20, 2026

View → Q1 termination

ULTRAGENYX PHARMACEUTICAL

1st Quarter 2026 (Jan 1 - Mar 31) · posted Apr 20, 2026

View → Q1 report

ACT FOR ULTRA RARE

1st Quarter 2026 (Jan 1 - Mar 31) · House · $37,500 income · posted Apr 20, 2026

View → Q1 reportNo activity

TAYSHA GENE THERAPIES

1st Quarter 2026 (Jan 1 - Mar 31) · posted Apr 17, 2026

View → Q1 reportNo activity

BEAM THERAPEUTICS

1st Quarter 2026 (Jan 1 - Mar 31) · posted Apr 17, 2026

View → Q1 reportNo activity

HUNTINGTON'S DISEASE SOCIETY OF AMERICA

1st Quarter 2026 (Jan 1 - Mar 31) · $22,500 income · posted Apr 17, 2026

View → Q1 report

ELEMENT BIOSCIENCES

1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $39,000 income · posted Apr 17, 2026

View →

Showing the 20 most recent of 45 filings. Search the explorer for "AVIVA STRATEGIES (FKA MGB CONSULTING)".

Keep going

Filings through October 19, 2026, the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.